IXICO PLC (GB:IXI)
LSE:IXI
Want to see GB:IXI full AI Analyst Report?
Top Page
IXICO plc
(LSE:IXI)
Select Model
Select Model
Rating:61Neutral
Price Target:
9.00 p
▼(-23.40% Downside)
Action:Reiterated
Date:05/22/26
The score is primarily constrained by weak underlying financial performance (ongoing losses and negative operating cash flow). Offsetting this, the latest earnings call showed strong commercial momentum and improved operating leverage with high revenue visibility and a strengthened cash position after the capital raise. Technicals are supportive but appear overbought, and valuation remains pressured due to unprofitability and no dividend data.
Positive Factors
Record order book & revenue visibility
An £18.1m order book that provides ~95% coverage of FY26 guidance materially raises medium-term revenue visibility. This durable backlog supports planning, staffing, and capital allocation, reduces quarter-to-quarter volatility and improves the probability of converting pipeline into contracted revenue and margins over the next 2–6 months.
Negative Factors
Persistent losses and weak cash generation
Ongoing net losses and negative operating cash flow limit the company's ability to self-fund TechBio productization and commercial expansion. Reliance on external capital increases dilution and execution risk; until consistent positive cash generation occurs, balance sheet and funding remain structural constraints on growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Record order book & revenue visibility
An £18.1m order book that provides ~95% coverage of FY26 guidance materially raises medium-term revenue visibility. This durable backlog supports planning, staffing, and capital allocation, reduces quarter-to-quarter volatility and improves the probability of converting pipeline into contracted revenue and margins over the next 2–6 months.
Read all positive factors
IXICO plc (IXI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£18.53M
Dividend YieldN/A
Average Volume (3M)123.87K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth13.04%
EPS Growth15.88%
CountryUK
Employees81
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding218,047,590
10 Day Avg. Volume82,815
30 Day Avg. Volume123,868
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£7.50M
IXICO plc Business Overview & Revenue Model
Company Description
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, a...
How the Company Makes Money
IXICO makes money primarily by providing services to life sciences customers (e.g., pharma/biotech companies and clinical research stakeholders) involved in clinical trials, especially CNS trials. Its revenue model is largely project- and contract...
IXICO plc Earnings Call Summary
Earnings Call Date:May 19, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Dec 08, 2026
Earnings Call Sentiment Positive
The call conveyed solid operational progress and strong commercial momentum: double-digit revenue growth (23% in H1), a record GBP 18.1m order book providing 95% coverage of FY26 guidance, improved gross margin (53%), a narrowed EBITDA loss (GBP 0.5m), a successful GBP 10m capital raise and a strategic Medidata partnership that supports productization and scaling. Offsetting these positives are continuing near-term losses, timing risk for TechBio-derived recurring revenue due to productization and regulatory timelines, some exposure to trial descopes/cancellations and the need to convert an increasingly promising pipeline into contracted revenue in large indications like Alzheimer’s and Parkinson’s. Overall, the momentum and balance sheet reinforcement from the capital raise materially outweigh the near-term investment-driven drawbacks, but investors should note the multi-year horizon to realize TechBio recurring revenue and the stated 2029 target for sustained profitability.Positive Updates
Strong Revenue Growth
Revenue for H1 FY26 was GBP 3.9m, a 23% increase versus H1 FY25, ahead of the company's 15% full-year growth guidance.
Negative Updates
Ongoing Net Losses and Near-Term EBITDA Impact
Despite narrowed losses, the business remained EBITDA negative (GBP 0.5m loss in H1). Management expects further short-term EBITDA impact due to continued TechBio investments and has pushed sustainable profitability target to 2029.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Revenue for H1 FY26 was GBP 3.9m, a 23% increase versus H1 FY25, ahead of the company's 15% full-year growth guidance.
Read all positive updates
Company Guidance
The company reiterated full‑year revenue guidance of GBP 7.5m (15% growth target) after a strong H1: revenues of GBP 3.9m (+23% YoY), 53% gross margin and an EBITDA loss narrowed to GBP 0.5m; management said the record order book of GBP 18.1m (up 31% since year‑end and 38% vs H1 2025) provides ~95% visibility of this year’s guidance. Over the last 12 months IXICO recognized GBP 7.2m of revenue, signed GBP 12.6m of new contracts (book‑to‑bill 1.75) and now has its largest project at 19% of order book; cash at half‑year was GBP 1.7m, augmented by GBP 9.4m net raise to GBP 10.8m at end‑April, with net assets GBP 10.7m (long‑term assets ~GBP 8m, working capital ~GBP 3.3m, lease liabilities ~GBP 0.5m). Management expects sustainable profitability and positive cash flow by 2029, will keep capex at c. GBP 300k per half (plus recent ~GBP 100k IT and ~GBP 100k refurb), aims to productize 2–3 TechBio products this year and targets FDA/software‑as‑medical‑device regulatory work on a 18–24 month horizon.IXICO plc Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.28M | 6.53M | 5.77M | 6.67M | 8.64M | 9.19M |
| Gross Profit | 3.51M | 2.91M | 2.71M | 3.27M | 4.77M | 5.53M |
| EBITDA | -2.33M | -2.02M | -1.95M | -707.00K | 1.55M | 1.73M |
| Net Income | -1.82M | -1.65M | -2.00M | -1.18M | 1.03M | 1.51M |
Balance Sheet | ||||||
| Total Assets | 12.99M | 13.84M | 11.19M | 12.99M | 14.65M | 14.26M |
| Cash, Cash Equivalents and Short-Term Investments | 1.68M | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M |
| Total Debt | 559.00K | 179.00K | 314.00K | 387.00K | 516.00K | 597.00K |
| Total Liabilities | 2.27M | 2.10M | 1.72M | 1.56M | 2.16M | 2.78M |
| Stockholders Equity | 10.72M | 11.74M | 9.46M | 11.43M | 12.49M | 11.48M |
Cash Flow | ||||||
| Free Cash Flow | -2.17M | -934.00K | -2.20M | -1.66M | -815.00K | -1.54M |
| Operating Cash Flow | -2.02M | -883.00K | -1.73M | 302.00K | 1.43M | 614.00K |
| Investing Cash Flow | -1.11M | -870.00K | -377.00K | -1.86M | -2.25M | -2.15M |
| Financing Cash Flow | -202.00K | 3.50M | -134.00K | -156.00K | -114.00K | 270.00K |
IXICO plc Technical Analysis
Neutral
11.75
Price Trends
7.41
Positive
8.75
Negative
10.24
Negative
Market Momentum
0.17
Negative
80.41
Negative
85.04
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Neutral. The current price of 11.75 is above the 20-day moving average (MA) of 7.10, above the 50-day MA of 7.41, and above the 200-day MA of 10.24, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 80.41 is Negative, neither overbought nor oversold. The STOCH value of 85.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:IXI.
IXICO plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | £18.53M | -4.43 | -15.57% | ― | 13.04% | 15.88% | |
53 Neutral | £2.49M | -0.72 | -89.43% | ― | 91.27% | 60.98% | |
53 Neutral | £55.07M | -1.83 | -14.65% | 2.94% | -25.43% | -155.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | £354.30M | -1.74 | -361.23% | ― | ― | ― | |
40 Underperform | £8.15M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
40 Underperform | £19.87M | -6.19 | -213.66% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:IXI
IXICO plc
8.65
-2.85
-24.78%
GB:AVCT
Avacta Group plc
78.10
49.85
176.46%
GB:OBD
Oxford BioDynamics
0.19
-0.13
-40.63%
GB:PYC
Physiomics
0.65
0.23
54.76%
GB:HVO
Open Orphan Plc
8.10
-8.80
-52.07%
GB:APTA
Aptamer Group Plc
0.58
0.20
55.41%
IXICO plc Corporate Events
Business Operations and StrategyFinancial Disclosures
IXICO to outline growth strategy at Mello2026 investor event
Positive
May 22, 2026
IXICO plc will present to private investors at the Mello2026 conference in London on 3 June 2026, highlighting its recent positive financial results. Chief executive Bram Goorden is set to outline the company’s current growth trajectory and ...
Business Operations and Strategy
IXICO Wins £1.3m Neuroscience Imaging Contracts in Alzheimer’s and Huntington’s Trials
Positive
May 21, 2026
IXICO plc has secured a new contract and a clinical trial extension worth a combined £1.3 million over two years, underscoring its growing role in neurological drug and diagnostics development. The company will supply amyloid PET imaging anal...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
IXICO boosts revenue and order book as it doubles down on TechBio strategy
Positive
May 19, 2026
IXICO reported a 23% rise in interim revenues to £3.9 million, driven by new contracts, extensions and higher analysis volumes in its imaging CRO business, while gross margin improved to 53% and EBITDA losses narrowed to £0.5 million. Th...
Business Operations and StrategyProduct-Related Announcements
IXICO launches upgraded AI neuroimaging platform to drive TechBio expansion
Positive
May 12, 2026
IXICO has launched version 10 of its proprietary IXI neuroimaging platform, an AI-enabled system designed specifically for neurological disease research and clinical trials. The updated release enhances image-reading precision, boosts data process...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
IXICO Confirms Equity Issue as Directors Back Fundraising Ahead of AIM Admission
Positive
Apr 22, 2026
IXICO plc, a specialist in AI-powered neuroscience imaging analytics for neurological drug development, has confirmed that all conditions for its previously announced first placing and subscription have been met following receipt of HM Revenue Cu...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
IXICO posts strong H1 growth and bolsters cash for AI-driven neurology push
Positive
Apr 21, 2026
IXICO reported a strong first half to 2026, with revenues expected to rise 23% to £3.9 million, driven by new contract wins, extensions and higher biomarker analysis volumes. The company also anticipates an improved gross margin of 53% and an...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
IXICO posts strong first-half growth and secures £10m to drive Tech Bio strategy
Positive
Apr 21, 2026
IXICO plc, a neuroscience imaging and biomarker analytics company, reported another period of robust growth for the six months to 31 March 2026, with revenues expected to rise 23% to £3.9m and gross margin improving to 53%, driven by new cont...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
IXICO wins shareholder backing for equity raise but faces brief delay to share admission
Neutral
Apr 16, 2026
IXICO plc said shareholders have approved all resolutions at a general meeting tied to its previously announced placings, subscription and retail offer, granting directors authority to allot new shares and implement a new non-employee sub-plan und...
Business Operations and StrategyPrivate Placements and Financing
IXICO raises £10 million through staged share issue and retail offer
Positive
Apr 7, 2026
IXICO plc has closed its recently launched UK retail offer, raising £30,320 through the issue of 379,000 new shares at 8.0 pence each, as part of a wider fundraising. Together with associated placings and a subscription priced at the same lev...
Business Operations and StrategyPrivate Placements and Financing
IXICO Opens Retail Share Offer as Part of £10.5m Fundraising Drive
Positive
Mar 31, 2026
IXICO plc has launched a retail offer in the UK for up to 6.25 million new ordinary shares at 8 pence each via the BookBuild platform, alongside previously announced placings and a subscription that together aim to raise £10 million before ex...
Business Operations and StrategyPrivate Placements and Financing
IXICO targets up to £10.5m equity raise to scale AI neurology platform
Positive
Mar 31, 2026
IXICO plans to raise up to £10.5 million through a two‑stage placing, a director subscription and a retail offer, issuing new shares at 8 pence, a small premium to the prior closing price. The first placing and director subscription of ...
Business Operations and Strategy
IXICO links AI neuroimaging platform with Medidata to boost CNS clinical trials
Positive
Mar 26, 2026
IXICO has entered a technology collaboration with Medidata, a Dassault Systèmes brand and major clinical trial solutions provider, to connect its IXI Platform with the Medidata Platform and create an integrated neuroimaging data and analysis ...
Business Operations and StrategyProduct-Related Announcements
IXICO links AI neuroimaging platform with Medidata to boost CNS clinical trials
Positive
Mar 26, 2026
IXICO plc, a specialist in AI-enabled neuroimaging and biomarker analytics for neurological clinical trials, has aligned its IXI Platform with Medidata’s clinical trial solutions to create an integrated neuroimaging data and analysis offerin...
Business Operations and StrategyProduct-Related Announcements
IXICO’s AI Imaging Platform Matches and Surpasses Gold Standard in Brain Atrophy Measurement
Positive
Feb 26, 2026
IXICO has reported new validation data showing that the automated brain volume measurement capabilities within its AI-driven IXI neuroimaging platform match, and in some measures exceed, the performance of the traditional semi-manual Boundary Shif...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.